B. Rogula

Publications23
h-index5
Citations156
Highly Influential Citations2
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Wagg
  • 368 Publications • 5,688 Citations
  • C. Chapple
  • 1,246 Publications • 31,098 Citations
  • S. Herschorn
  • 389 Publications • 11,783 Citations
  • E. Siddiqui
  • 92 Publications • 2,366 Citations
  • Publications
  • Influence
Evaluating adverse drug event reporting in administrative data from emergency departments: a validation study
TLDR
Adverse drug events to outpatient medications were underreported in emergency department administrative data compared to the number of adverse drug events diagnosed and recorded at the point-of-care.
View on Springer
The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.
View on PubMed
Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
TLDR
Higher levels of anticholinergic burden are associated with higher rates of falls and fractures, highlighting the importance of considering anticholergic burden when treating patients with OAB.
View on BMJ
The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: a population-based observational study
TLDR
Despite similar death rates in the semiurgent and nonurgent groups, the longer waiting times in the nonurgen group result in a greater cumulative incidence of death on the wait list compared to that in the Semiurgent group.
View on Springer
Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis
TLDR
It is indicated that the safety and efficacy profile of mirabegron remains favorable compared with antimuscarinics among older adults, which includes safety outcomes typically associated with anticholinergic burden, which were less frequently observed in patients treated with mirabEGron.
View on Springer
An Observational Study to Evaluate 2 Target Times for Elective Coronary Bypass Surgery
TLDR
The findings suggest a survival benefit from performing elective surgical revascularization within the time frame recommended by the stricter of the 2 guidelines, and have implications for health systems that provide universal coverage and that budget the annual number of procedures.
View on Wolters Kluwer
Evaluation of supply-side initiatives to improve access to coronary bypass surgery
TLDR
Waiting times for non-emergency coronary bypass surgery shortened after supplementary funding was granted to increase volume of cardiac surgical care in a health system with publicly-funded universal coverage for the procedure.
View on Springer
Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder
TLDR
Falls/fractures were associated with higher costs, which increased with increasing anticholinergic burden, and annual costs were predicted according to age, sex, fall/f Fracture status, and level of anticholergic burden.
View on Springer
An Evaluation of Longitudinal Measures of Anticholinergic Exposure for Application in Retrospective Administrative Data Analyses
TLDR
Considering both potency and dose, the CAB may prove a more comprehensive measure of anticholinergic burden; however, additional research is necessary to demonstrate whether it has any association with relevant health-related outcomes.
View on Springer
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States
Treatment patterns and costs were characterized among patients with overactive bladder (OAB) receiving later‐line target therapies (combination mirabegron/antimuscarinic, sacral nerve stimulation…
View on Wiley
...
...